Anbar HS - Search Results

1

Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.

Zaraei SO, Sbenati RM, Alach NN, Anbar HS, El-Gamal R, Tarazi H, Shehata MK, Abdel-Maksoud MS, Oh CH, El-Gamal MI. Zaraei SO, et al. Among authors: anbar hs. Eur J Med Chem. 2021 Nov 15;224:113674. doi: 10.1016/j.ejmech.2021.113674. Epub 2021 Jun 29. Eur J Med Chem. 2021. PMID: 34237622

2

Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.

Chang JS, El-Gamal MI, Lee WS, Anbar HS, Chung HJ, Kim HI, Cho YJ, Lee BS, Lee SA, Moon JY, Lee DJ, Jeon HR, Lee J, Choi YW, Oh CH. Chang JS, et al. Among authors: anbar hs. Eur J Med Chem. 2011 Sep;46(9):3564-9. doi: 10.1016/j.ejmech.2011.05.019. Epub 2011 May 13. Eur J Med Chem. 2011. PMID: 21641692

3

FMS Kinase Inhibitors: Current Status and Future Prospects.

El-Gamal MI, Anbar HS, Yoo KH, Oh CH. El-Gamal MI, et al. Among authors: anbar hs. Med Res Rev. 2013 May;33(3):599-636. doi: 10.1002/med.21258. Epub 2012 Mar 20. Med Res Rev. 2013. PMID: 22434539 Review.

4

Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.

El-Gamal MI, Anbar HS, Chung HJ, Kim HI, Cho YJ, Lee BS, Lee SA, Moon JY, Lee DJ, Kwon D, Choi WJ, Jeon HR, Oh CH. El-Gamal MI, et al. Among authors: anbar hs. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1347-50. doi: 10.1016/j.bmcl.2012.12.090. Epub 2013 Jan 4. Bioorg Med Chem Lett. 2013. PMID: 23347686

5

Recent advances of pyrrolopyridines derivatives: a patent and literature review.

El-Gamal MI, Anbar HS. El-Gamal MI, et al. Among authors: anbar hs. Expert Opin Ther Pat. 2017 May;27(5):591-606. doi: 10.1080/13543776.2017.1280465. Epub 2017 Jan 27. Expert Opin Ther Pat. 2017. PMID: 28064544 Review.

6

Synthesis, biological evaluation, and molecular docking study of sulfonate derivatives as nucleotide pyrophosphatase/phosphodiesterase (NPP) inhibitors.

Semreen MH, El-Gamal MI, Ullah S, Jalil S, Zaib S, Anbar HS, Lecka J, Sévigny J, Iqbal J. Semreen MH, et al. Among authors: anbar hs. Bioorg Med Chem. 2019 Jul 1;27(13):2741-2752. doi: 10.1016/j.bmc.2019.04.031. Epub 2019 Apr 26. Bioorg Med Chem. 2019. PMID: 31088715

7

Sulfamates in drug design and discovery: Pre-clinical and clinical investigations.

Zaraei SO, Abduelkarem AR, Anbar HS, Kobeissi S, Mohammad M, Ossama A, El-Gamal MI. Zaraei SO, et al. Among authors: anbar hs. Eur J Med Chem. 2019 Oct 1;179:257-271. doi: 10.1016/j.ejmech.2019.06.052. Epub 2019 Jun 22. Eur J Med Chem. 2019. PMID: 31255926 Review.

8

Sulfonate and sulfamate derivatives possessing benzofuran or benzothiophene nucleus as potent carbonic anhydrase II/IX/XII inhibitors.

Zaraei SO, El-Gamal MI, Shafique Z, Amjad ST, Afridi S, Zaib S, Anbar HS, El-Gamal R, Iqbal J. Zaraei SO, et al. Among authors: anbar hs. Bioorg Med Chem. 2019 Sep 1;27(17):3889-3901. doi: 10.1016/j.bmc.2019.07.026. Epub 2019 Jul 13. Bioorg Med Chem. 2019. PMID: 31345748

9

Synthesis, biological evaluation, and docking studies of new raloxifene sulfonate or sulfamate derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase.

El-Gamal MI, Ullah S, Zaraei SO, Jalil S, Zaib S, Zaher DM, Omar HA, Anbar HS, Pelletier J, Sévigny J, Iqbal J. El-Gamal MI, et al. Among authors: anbar hs. Eur J Med Chem. 2019 Nov 1;181:111560. doi: 10.1016/j.ejmech.2019.07.063. Epub 2019 Jul 25. Eur J Med Chem. 2019. PMID: 31382118

10

Discovery of a potent p38α/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies.

El-Gamal MI, Anbar HS, Tarazi H, Oh CH. El-Gamal MI, et al. Among authors: anbar hs. Eur J Med Chem. 2019 Dec 1;183:111684. doi: 10.1016/j.ejmech.2019.111684. Epub 2019 Sep 8. Eur J Med Chem. 2019. PMID: 31520926

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page